Identification of overlapping HLA class I-restricted cytotoxic T cell epitopes in a conserved region of the human immunodeficiency virus type 1 envelope glycoprotein: definition of minimum epitopes and analysis of the effects of sequence variation - PubMed (original) (raw)
Identification of overlapping HLA class I-restricted cytotoxic T cell epitopes in a conserved region of the human immunodeficiency virus type 1 envelope glycoprotein: definition of minimum epitopes and analysis of the effects of sequence variation
R P Johnson et al. J Exp Med. 1992.
Abstract
Although the immunologic basis of protective immunity in human immunodeficiency virus type 1 (HIV-1) infection has not yet been defined, virus-specific cytotoxic T lymphocytes (CTL) are likely to be an important host defense and may be a critical feature of an effective vaccine. These observations, along with the inclusion of the HIV-1 envelope in the majority of vaccine candidates presently in clinical trials, underscore the importance of the precise characterization of the cellular immune responses to this protein. Although humoral immune responses to the envelope protein have been extensively characterized, relatively little information is available regarding the envelope epitopes recognized by virus-specific CTL and the effects of sequence variation within these epitopes. Here we report the identification of two overlapping CTL epitopes in a highly conserved region of the HIV-1 transmembrane envelope protein, gp41, using CTL clones derived from two seropositive subjects. An eight-amino acid peptide was defined as the minimum epitope recognized by HLA-B8-restricted CTL derived from one subject, and in a second subject, an overlapping nine-amino acid peptide was identified as the minimal epitope for HLA-B14-restricted CTL clones. Selected single amino acid substitutions representing those found in naturally occurring HIV-1 isolates resulted in partial to complete loss of recognition of these epitopes. These data indicate the presence of a highly conserved region in the HIV-1 envelope glycoprotein that is immunogenic for CTL responses. In addition, they suggest that natural sequence variation may lead to escape from immune detection by HIV-1-specific CTL. Since the region containing these epitopes has been previously shown to contain an immunodominant B cell epitope and also overlaps with a major histocompatibility complex class II T cell epitope recognized by CD4+ CTL from HIV-1 rgp160 vaccine recipients, it may be particularly important for HIV-1 vaccine development. Finally, the identification of minimal CTL epitopes presented by class I HLA molecules should facilitate the definition of allele-specific motifs.
Similar articles
- Recognition of a highly conserved region of human immunodeficiency virus type 1 gp120 by an HLA-Cw4-restricted cytotoxic T-lymphocyte clone.
Johnson RP, Trocha A, Buchanan TM, Walker BD. Johnson RP, et al. J Virol. 1993 Jan;67(1):438-45. doi: 10.1128/JVI.67.1.438-445.1993. J Virol. 1993. PMID: 7677956 Free PMC article. - Identification of highly conserved and broadly cross-reactive HIV type 1 cytotoxic T lymphocyte epitopes as candidate immunogens for inclusion in Mycobacterium bovis BCG-vectored HIV vaccines.
Ferrari G, Kostyu DD, Cox J, Dawson DV, Flores J, Weinhold KJ, Osmanov S. Ferrari G, et al. AIDS Res Hum Retroviruses. 2000 Sep 20;16(14):1433-43. doi: 10.1089/08892220050140982. AIDS Res Hum Retroviruses. 2000. PMID: 11018863 Review.
Cited by
- Immunoescape of HIV-1 in Env-EL9 CD8 + T cell response restricted by HLA-B*14:02 in a Non progressor who lost twenty-seven years of HIV-1 control.
Moyano A, Blanch-Lombarte O, Tarancon-Diez L, Pedreño-Lopez N, Arenas M, Alvaro T, Casado C, Olivares I, Vera M, Rodriguez C, Del Romero J, López-Galíndez C, Ruiz-Mateos E, Prado JG, Pernas M. Moyano A, et al. Retrovirology. 2022 Mar 26;19(1):6. doi: 10.1186/s12977-022-00591-7. Retrovirology. 2022. PMID: 35346235 Free PMC article. - Specificity of CD8+ T-Cell Responses Following Vaccination with Conserved Regions of HIV-1 in Nairobi, Kenya.
Mohamed YS, Borthwick NJ, Moyo N, Murakoshi H, Akahoshi T, Siliquini F, Hannoun Z, Crook A, Hayes P, Fast PE, Mutua G, Jaoko W, Silva-Arrieta S, Llano A, Brander C, Takiguchi M, Hanke T. Mohamed YS, et al. Vaccines (Basel). 2020 May 29;8(2):260. doi: 10.3390/vaccines8020260. Vaccines (Basel). 2020. PMID: 32485938 Free PMC article. - HLA-B*14:02-Restricted Env-Specific CD8+ T-Cell Activity Has Highly Potent Antiviral Efficacy Associated with Immune Control of HIV Infection.
Leitman EM, Willberg CB, Tsai MH, Chen H, Buus S, Chen F, Riddell L, Haas D, Fellay J, Goedert JJ, Piechocka-Trocha A, Walker BD, Martin J, Deeks S, Wolinsky SM, Martinson J, Martin M, Qi Y, Sáez-Cirión A, Yang OO, Matthews PC, Carrington M, Goulder PJR. Leitman EM, et al. J Virol. 2017 Oct 27;91(22):e00544-17. doi: 10.1128/JVI.00544-17. Print 2017 Nov 15. J Virol. 2017. PMID: 28878089 Free PMC article. Clinical Trial. - Design and pre-clinical evaluation of a universal HIV-1 vaccine.
Létourneau S, Im EJ, Mashishi T, Brereton C, Bridgeman A, Yang H, Dorrell L, Dong T, Korber B, McMichael AJ, Hanke T. Létourneau S, et al. PLoS One. 2007 Oct 3;2(10):e984. doi: 10.1371/journal.pone.0000984. PLoS One. 2007. PMID: 17912361 Free PMC article. - Limited sequence evolution within persistently targeted CD8 epitopes in chronic human immunodeficiency virus type 1 infection.
Koibuchi T, Allen TM, Lichterfeld M, Mui SK, O'Sullivan KM, Trocha A, Kalams SA, Johnson RP, Walker BD. Koibuchi T, et al. J Virol. 2005 Jul;79(13):8171-81. doi: 10.1128/JVI.79.13.8171-8181.2005. J Virol. 2005. PMID: 15956562 Free PMC article.
References
- Nature. 1990 Nov 29;348(6300):388 - PubMed
- J Exp Med. 1988 Dec 1;168(6):2045-57 - PubMed
- Int Immunol. 1990;2(8):707-12 - PubMed
- Nature. 1990 Nov 15;348(6298):248-51 - PubMed
- AIDS. 1990 Nov;4(11):1095-103 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials